Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-011 in Lipoprotein Lipase Deficiency
NCT01109498Phase 3Unknown
- Sponsor
- Amsterdam Molecular Therapeutics
- Start
- Aug 2007
- Primary completion
- Jun 2013
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 3 trial of alipogene tiparvovec in familial lipoprotein lipase deficiency (LPLD), sponsored by Amsterdam Molecular Therapeutics. Status: unknown.
02
Drugs
alipogene tiparvovec
03
Conditions
familial lipoprotein lipase deficiency (LPLD)
Beyond the preview
Go deeper on NCT01109498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01109498.